ATE429230T1 - CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT - Google Patents

CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT

Info

Publication number
ATE429230T1
ATE429230T1 AT03740769T AT03740769T ATE429230T1 AT E429230 T1 ATE429230 T1 AT E429230T1 AT 03740769 T AT03740769 T AT 03740769T AT 03740769 T AT03740769 T AT 03740769T AT E429230 T1 ATE429230 T1 AT E429230T1
Authority
AT
Austria
Prior art keywords
cancer treatment
chinazoline derivatives
derivatives
chinazoline
treatment
Prior art date
Application number
AT03740769T
Other languages
German (de)
Inventor
Laurent Hennequin
Kevin Foote
Keith Gibson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0215825A external-priority patent/GB0215825D0/en
Priority claimed from GB0312897A external-priority patent/GB0312897D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE429230T1 publication Critical patent/ATE429230T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
AT03740769T 2002-07-09 2003-07-04 CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT ATE429230T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0215825A GB0215825D0 (en) 2002-07-09 2002-07-09 Quinazoline derivatives
GB0312897A GB0312897D0 (en) 2003-06-05 2003-06-05 Quinazoline derivatives
PCT/GB2003/002874 WO2004004732A1 (en) 2002-07-09 2003-07-04 Quinazoline derivatives for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE429230T1 true ATE429230T1 (en) 2009-05-15

Family

ID=30117104

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740769T ATE429230T1 (en) 2002-07-09 2003-07-04 CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT

Country Status (7)

Country Link
US (1) US7504408B2 (en)
EP (1) EP1528925B1 (en)
JP (1) JP2005536486A (en)
AT (1) ATE429230T1 (en)
AU (1) AU2003281193A1 (en)
DE (1) DE60327323D1 (en)
WO (1) WO2004004732A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
SI1562955T1 (en) 2002-11-04 2008-06-30 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
JP4936897B2 (en) 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyrido- and pyrimidopyrimidine derivatives as antiproliferative agents
JO3088B1 (en) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv Macrocyclic Quinazoline derivatives and their use as MTKI
NI200700147A (en) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP
JP2009542778A (en) * 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ MTKI quinazoline derivative
UY31137A1 (en) * 2007-06-14 2009-01-05 Smithkline Beecham Corp DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA
AR092289A1 (en) 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd DERIVATIVES OF AMINOQUINAZOLINE AND ITS SALTS AND METHODS OF USE
CN105037279B (en) * 2015-06-25 2017-11-03 贵州大学 4 N substituted quinazolines analog derivatives of the structure containing pentadienone and preparation and application
BR112018006873A2 (en) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York autophageal flow activators and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN105753793B (en) * 2016-01-19 2018-09-04 河北医科大学 Fragrant formyl urea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89028A0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DE69622183D1 (en) 1995-11-07 2002-08-08 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLE DERIVATIVES, WHICH INHIBIT THE AUTOPHOSPHORYLATION OF THE GROWTH FACTOR RECEPTOR DERIVING FROM BLOOD PLATPLES AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
EA004436B1 (en) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
CN1167422C (en) * 1999-02-10 2004-09-22 阿斯特拉曾尼卡有限公司 Quinazoline derivatives as angiogenesis inhibitors
CA2384282A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
PL202812B1 (en) * 2000-08-21 2009-07-31 Astrazeneca Ab Quinazoline derivatives
JP4307843B2 (en) * 2001-04-19 2009-08-05 アストラゼネカ アクチボラグ Quinazoline derivatives
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
GB0128109D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0128122D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AU2002365664A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
EP1528925B1 (en) 2009-04-22
AU2003281193A1 (en) 2004-01-23
US7504408B2 (en) 2009-03-17
EP1528925A1 (en) 2005-05-11
DE60327323D1 (en) 2009-06-04
WO2004004732A1 (en) 2004-01-15
JP2005536486A (en) 2005-12-02
US20050250797A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
NO20025792D0 (en) Quinazoline derivatives for the treatment of tumors
DE60215178D1 (en) QUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF TYROSINE KINASE
ATE452129T1 (en) N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
MY129809A (en) Quinazoline derivatives
ATE409185T1 (en) QUINAZOLINE DERIVATIVES
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
DE602005008065D1 (en) OF PHOSPHATIDYLINOSITE- (PI-) 3-KINASE AND ITS USE IN THE TREATMENT OF CANCER
DE602004004811D1 (en) quinazoline derivatives
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
BR0315580A (en) Methylene Urea Derivatives
TW200510392A (en) Chemical compounds
DE60001974D1 (en) DERIVATIVES OF FLAVONES, XANTHONES AND CUMARINES
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
ATE482955T1 (en) AZABICYCLOOCTAN-3 DERIVATIVES AND THEIR USE
TW200505452A (en) Chemical compounds
ATE429230T1 (en) CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT
ATE233754T1 (en) DIPHENYL-PIPERIDINE DERIVATIVES
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
ATE424200T1 (en) SOLUBILIZED TOPOISOMERASE POISON AGENT
TW200420567A (en) Quinazoline derivatives
ATE353231T1 (en) PHARMACEUTICAL COMPOSITIONS
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties